Insulin degludec - A new-generation basal insulin

Ammar Wakil, Stephen L. Atkin

Research output: Contribution to journalReview article

4 Citations (Scopus)


Insulin degludec may provide dosing options for patients who, because of their lifestyle, require some flexibility in adhering to an insulin regimen, and it may also reduce the risk of hypoglycemia compared with the basal insulins that are currently available.

Original languageEnglish
Pages (from-to)539-542
Number of pages4
JournalExpert Opinion on Biological Therapy
Issue number5
Publication statusPublished - 1 May 2012



  • flexible dosing regimen
  • hypoglycemia
  • insulin degludec
  • type 1 and type 2 diabetes
  • ultra-long-acting basal insulin

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this